2020
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
Hegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, Byrd TT, Hicks J, Xu ML, Gerken C, Kalra M, Robertson C, Zhang H, Shree A, Mehta B, Dakhova O, Salsman VS, Grilley B, Gee A, Dotti G, Heslop HE, Brenner MK, Wels WS, Gottschalk S, Ahmed N. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nature Communications 2020, 11: 3549. PMID: 32669548, PMCID: PMC7363864, DOI: 10.1038/s41467-020-17175-8.Peer-Reviewed Original ResearchConceptsHER2-CAR T cellsCAR T cellsT-cell infusionCAR T-cell infusionT cellsMetastatic rhabdomyosarcomaOngoing phase I trialPhase I trialT cell receptorSecond remissionI trialSerum autoantibodiesImmune reactivityDetectable diseaseTumor responseBone marrowResponse consolidationInfusionRhabdomyosarcomaImmunodominant clonesLymphodepletionRemissionPathway proteinsDiseaseMonths
2019
Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study.
Rodriguez-Galindo C, Krailo MD, Krasin MJ, Huang L, McCarville MB, Hicks J, Pashankar F, Pappo AS. Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study. Journal Of Clinical Oncology 2019, 37: 3369-3376. PMID: 31553639, PMCID: PMC6920031, DOI: 10.1200/jco.19.01276.Peer-Reviewed Original ResearchConceptsEvent-free survivalChildhood nasopharyngeal carcinomaInduction chemotherapyConcurrent chemoradiotherapyStage IIBNasopharyngeal carcinomaCycles of ICCancer stage IIBPediatric-specific studiesCycles of cisplatinOverall survival estimatesAmerican Joint CommitteeDoses of cisplatinCumulative incidence estimatesRadiation dose reductionAdult regimensStable diseaseAdvanced diseasePartial responseMedian ageExcellent outcomesIncidence estimatesDose reductionPatientsJoint Committeeα‐Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium
O’Neill A, Xia C, Krailo MD, Shaikh F, Pashankar FD, Billmire DF, Olson TA, Amatruda JF, Villaluna D, Huang L, Malogolowkin M, Rodriguez‐Galindo C, Frazier AL. α‐Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium. Cancer 2019, 125: 3649-3656. PMID: 31355926, DOI: 10.1002/cncr.32363.Peer-Reviewed Original ResearchConceptsGerm cell tumorsChildren's Oncology GroupCell tumorsAFP declineCumulative incidenceOncology GroupOverall survivalPediatric patientsThree-year overall survivalFuture clinical trial designTumor marker declineStart of chemotherapyPredictors of outcomeRecognition of patientsClinical trial designYears of ageAdult patientsPoor prognosisSerum AFPMarker declineStratified analysisHigh riskTrial designPatientsEarly intensificationSustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed Hepatoblastoma
Natarajan E, Auerbach C, Cheron R, Pashankar F. Sustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed Hepatoblastoma. Journal Of Pediatric Hematology/Oncology 2019, 42: e659-e661. PMID: 31259823, DOI: 10.1097/mph.0000000000001544.Peer-Reviewed Original ResearchConceptsRecurrent hepatoblastomaIfosfamide/carboplatin/etoposide chemotherapyLong-term disease-free survivalCarboplatin/etoposide chemotherapyDisease-free survivalLimited treatment optionsAdjuvant chemotherapySecond relapseEtoposide chemotherapyFirst relapseMultiple relapsesSurgical resectionPoor prognosisTreatment optionsMetastatic hepatoblastomaHepatoblastomaRelapseChemotherapyIrinotecanChildrenRemissionResectionPostresectionPatientsPrognosisGrowing Teratoma Syndrome After Chemotherapy For Ovarian Immature Teratoma
Imran H, Siddiqui AH, Wilson F, Pashankar F. Growing Teratoma Syndrome After Chemotherapy For Ovarian Immature Teratoma. Journal Of Pediatric Hematology/Oncology 2019, 42: e630-e633. PMID: 31205224, DOI: 10.1097/mph.0000000000001525.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansNeoplasm Recurrence, LocalOvarian NeoplasmsSyndromeTeratomaConceptsOvarian immature teratomaRecurrent immature teratomaImmature teratomaTeratoma syndromePediatric patientsMainstay of treatmentPostoperative chemotherapyGynecologic oncologistsPediatric oncologistsAdult providersChemotherapyPatientsOncologistsSyndromeTeratomaAdultsTreatmentSurgeryRecurrenceManagementMainstay
2018
Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group
Fonseca A, Xia C, Lorenzo AJ, Krailo M, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Billmire DF, Rodriguez-Galindo C, Frazier AL, Shaikh F. Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group. Journal Of Clinical Oncology 2018, 37: 396-402. PMID: 30576269, PMCID: PMC6553816, DOI: 10.1200/jco.18.00790.Peer-Reviewed Original ResearchConceptsMalignant germ cell tumorsTumor marker elevationNongerminomatous malignant germ cell tumorsAbnormal tumor markersGerm cell tumorsMarker elevationTumor markersRelapse surveillanceOncology GroupInitial diagnosisCell tumorsChildren's Oncology GroupDetection of relapseSingle-arm trialNormal tumor markersCase report formsAbnormal imagingCentral reviewMarker levelsPathology reportsRelapsePatientsPhase IIIReport formsComplete data
2015
Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative
Pashankar F, Hale JP, Dang H, Krailo M, Brady WE, Rodriguez-Galindo C, Nicholson JC, Murray MJ, Bilmire DF, Stoneham S, Arul GS, Olson TA, Stark D, Shaikh F, Amatruda JF, Covens A, Gershenson DM, Frazier AL. Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative. Cancer 2015, 122: 230-237. PMID: 26485622, PMCID: PMC5134834, DOI: 10.1002/cncr.29732.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAnalysis of VarianceBiopsy, NeedleChemotherapy, AdjuvantChildCohort StudiesDisease-Free SurvivalFemaleHumansImmunohistochemistryMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingOvarian NeoplasmsRegistriesRisk AssessmentSurvival AnalysisTeratomaYoung AdultConceptsImmature teratomaAdult clinical trialsGrade 1 diseaseOvarian immature teratomaRole of chemotherapyPostoperative chemotherapyPediatric patientsAdult trialsPediatric trialsPooled analysisClinical trialsStage IAdult womenTrialsChemotherapyCollaborative data setPatientsSurgeryTeratomaDiseaseWomen
2014
Surveillance After Initial Surgery for Pediatric and Adolescent Girls With Stage I Ovarian Germ Cell Tumors: Report From the Children's Oncology Group
Billmire DF, Cullen JW, Rescorla FJ, Davis M, Schlatter MG, Olson TA, Malogolowkin MH, Pashankar F, Villaluna D, Krailo M, Egler RA, Rodriguez-Galindo C, Frazier AL. Surveillance After Initial Surgery for Pediatric and Adolescent Girls With Stage I Ovarian Germ Cell Tumors: Report From the Children's Oncology Group. Journal Of Clinical Oncology 2014, 32: 465-470. PMID: 24395845, PMCID: PMC4876316, DOI: 10.1200/jco.2013.51.1006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAlpha-FetoproteinsAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCisplatinDisease-Free SurvivalEtoposideFemaleHumansInfantInfant, NewbornKaplan-Meier EstimateNeoplasm Recurrence, LocalNeoplasm StagingNeoplasm, ResidualNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsRadiographyRisk FactorsSalvage TherapyTime FactorsTreatment OutcomeConceptsMalignant ovarian germ cell tumorsStage I malignant ovarian germ cell tumorsOvarian germ cell tumorsEvent-free survivalGerm cell tumorsOverall survivalAlpha-fetoproteinRecurrent diseaseOncology GroupCell tumorsSuccessful Salvage ChemotherapyTumor marker elevationPercent of patientsKaplan-Meier methodChildren's Oncology GroupSerum tumor markersPredominant histologySalvage chemotherapyInitial surgeryMarker elevationMetastatic diseaseSurgical resectionMedian timeYolk sacTumor markers
2012
Management of Pancreatoblastoma in Children and Young Adults
Glick RD, Pashankar FD, Pappo A, LaQuaglia MP. Management of Pancreatoblastoma in Children and Young Adults. Journal Of Pediatric Hematology/Oncology 2012, 34: s47-s50. PMID: 22525406, DOI: 10.1097/mph.0b013e31824e3839.Peer-Reviewed Original ResearchConceptsAppropriate cross-sectional imagingComplete surgical resectionLarge retroperitoneal massMalignant pancreatic tumorsGoal of therapyHigh recurrence rateRare childhood tumorCross-sectional imagingYoung childrenAdjuvant chemotherapyCurative resectionNeoadjuvant chemotherapyMetastatic diseaseSurgical resectionInitial diagnosisRetroperitoneal massChemotherapeutic regimensRecurrence rateMean ageRare tumorPancreatic tumorsTissue diagnosisChildhood tumorsSectional imagingTumors